Core Viewpoint - The company forecasts a revenue growth of over 45% year-on-year for 2025, with adjusted net profit (excluding interest income and expenses) also expected to grow over 45% [1][2]. Group 1: Business Performance - The company's core business continues to grow rapidly, solidifying its position as an industry leader, with a projected global market share increase to 24% by 2025 [1]. - The company plans to sign 70 new iCMC projects in 2025, including 22 "winning molecule" projects, with over half being cutting-edge new molecule types or new indications [1]. - The establishment of 10 new PPQ projects, reaching a total of 18 by the end of 2025, lays a solid foundation for revenue growth in the commercialization phase [1]. Group 2: Profitability and Strategic Moves - The company expects a revenue growth rate exceeding 45% in 2025, with gross profit growth surpassing 70%, and adjusted net profit growth (excluding interest income and expenses) also exceeding 45%, with over 65% growth when excluding currency fluctuations [2]. - The company announced a strategic acquisition of Dongyao Pharmaceutical at a maximum total price of approximately HKD 2.79 billion, enhancing its capabilities in the ADC field and shortening capacity expansion cycles [2]. - The company plans to invest over RMB 7 billion from 2026 to 2029 for expansion of conjugation, formulation, and payload connection facilities, with an expansion rate exceeding the industry average [2]. Group 3: Earnings Forecast and Valuation - The company maintains its earnings forecasts for 2025 and 2026, while introducing a net profit forecast of RMB 3.1 billion for 2027 [2]. - The current stock price corresponds to an adjusted P/E of 36.9x for 2026 and 26.9x for 2027, with a target price raised by 17.3% to HKD 88, reflecting an upward potential of 16.2% [2].

Core Viewpoint - The company is expected to achieve strong revenue growth in 2025, with significant increases in gross profit and net profit, driven by robust order acquisition and capacity expansion [1][2]. Group 1: Financial Performance - The company forecasts a revenue increase of over 45%, gross profit growth exceeding 70%, and net profit growth of approximately 38% for 2025 [1]. - Expected revenue for 2025 is around 59.6 billion, with a gross profit of 21.1 billion and a net profit of 14.7 billion [1]. - The gross margin is projected to be approximately 35.4%, an increase of about 5 percentage points from 2024 [1]. Group 2: Project Pipeline and Market Position - The company signed 70 new iCMC projects in 2025, with over half being new molecular projects, indicating a strong pipeline for future growth [2]. - The global market share is expected to rise from 21.7% in 2024 to over 24% in 2025 [2]. Group 3: Capacity Expansion - The company is expanding its production capacity, with existing DP capacity in Wuxi being maintained and expanded, and new capacities in Singapore and other locations expected to come online between 2026 and 2028 [2]. - The acquisition of the Hefei base is expected to enhance POC development and production capabilities, with an annual capacity exceeding 40 kg for peptides [2]. Group 4: Strategic Acquisition - The company plans to acquire Dongyao Pharmaceutical for approximately 30.9 billion HKD, which will strengthen its competitive position in the market [3]. - Dongyao Pharmaceutical has significant production capabilities, including two antibody production lines and three independent ADC production workshops [3].

Core Viewpoint - WuXi AppTec's subsidiary, WuXi Biologics, announced a cash offer to acquire Dongyao Pharmaceutical at a 99% premium, with a maximum bid of HKD 2.79 billion, highlighting the competitive landscape in the ADC CRDMO sector driven by high outsourcing rates [1][2][3] Group 1: Acquisition Details - The acquisition involves a cash offer of HKD 4 per share, significantly higher than Dongyao's previous trading price of around HKD 2, indicating a premium that exceeds the typical range of 30%-50% [2][12] - The ADC market has seen explosive growth, with 21 ADC drugs approved globally by October 2025, leading to a scarcity of production capacity [2][12] - WuXi Biologics aims to enhance its production capabilities through this acquisition rather than building new facilities, which would take 3-5 years and require at least HKD 1 billion in capital [3][13] Group 2: Strategic Intent - The transaction structure allows Dongyao to maintain its listing status, becoming a subsidiary of WuXi Biologics, which can help both companies leverage their strengths for better performance [3][14] - WuXi Biologics holds a 24% market share in the global ADC CRDMO sector, with over 630 clients and 1,291 projects, indicating strong demand for its services [4][14] - The acquisition is expected to further boost WuXi Biologics' revenue growth, projected to exceed 45% in 2025, with gross profit growth over 70% [4][14] Group 3: Financial Position and Future Plans - WuXi Biologics has a robust financial position, having completed a USD 350 million refinancing and holding over USD 900 million in cash, which supports the acquisition [5][15] - The company plans to invest over HKD 7 billion in capital expenditures from 2026 to 2029, aiming for a global production capacity target by 2030 [5][16] - The new Singapore facility is expected to meet the highest GMP compliance standards and is set to begin operations in the first half of 2026 [5][16] Group 4: Industry Context - The ADC CRDMO sector is characterized by high outsourcing rates, with 70% for bioconjugates compared to 34% for biologics, leading to a growing capacity gap in the industry [2][12] - Dongyao Pharmaceutical, previously focused on ADC drug innovation, is transitioning to CRDMO services due to challenges in its core pipeline, making the acquisition a strategic fit [4][15]

Investment Rating - The investment rating for WuXi AppTec (2268 HK) is maintained at "Buy" with a target price of HKD 82.24 [8][14]. Core Insights - WuXi AppTec is expected to see significant revenue growth in 2025, with revenue, gross profit, net profit, and adjusted net profit projected to increase by over 45%, 70%, 38%, and 65% year-on-year, respectively [1][2]. - The company plans to acquire Dongyao Pharmaceutical for approximately HKD 3.09 billion, which is anticipated to enhance its competitive edge and capacity [5][6]. - The demand for Contract Research, Development, and Manufacturing Organization (CRDMO) services is expected to rise as global Antibody-Drug Conjugate (ADC) pipelines commercialize [1][3]. Revenue and Profit Forecast - Revenue for 2025 is estimated at approximately HKD 59.6 billion, with a gross profit of HKD 21.1 billion and a net profit of HKD 14.7 billion [2][12]. - The gross margin is projected to be around 35.4%, an increase of about 5 percentage points from 2024, indicating strong operational efficiency [2][12]. - Adjusted net profit is expected to grow by over 65% for the year, despite a decline in profit margins in the second half of 2025 due to foreign exchange impacts and rising expense ratios [2][12]. Project Pipeline - The company signed 70 new iCMC projects in 2025, with 22 being molecular projects, contributing to a total of 252 iCMC projects [3]. - WuXi AppTec is expected to lead in the development of new conjugated molecules, with over half of the new projects being innovative types [3]. - The global market share is projected to increase from 21.7% in 2024 to over 24% in 2025 [3]. Capacity Expansion - The company is expanding its production capacity, with existing DP capacity in Wuxi being maintained and expanded in 2025 [4]. - New production facilities in Singapore are expected to be operational by mid-2025, with additional overseas capacity coming online in 2026 [4]. - The acquisition of the Hefei base is expected to enhance peptide development and production capabilities, with an annual capacity exceeding 40 kg [4]. Acquisition of Dongyao - The acquisition of Dongyao Pharmaceutical is expected to strengthen WuXi AppTec's existing competitive position, as Dongyao has significant production capabilities and a strong client base [5][6]. - Dongyao operates two antibody bulk production lines and three independent ADC bulk production workshops, which will complement WuXi AppTec's offerings [5]. Earnings Forecast and Valuation - Adjusted net profit forecasts for 2025, 2026, and 2027 are revised to HKD 15.9 billion, HKD 22.4 billion, and HKD 31.6 billion, respectively, reflecting a CAGR of 39% [6][12]. - The target price is based on a PEG ratio of 1.06x for 2026, aligning with comparable companies in the sector [6][14].

（药明生物公告） 近日，药明生物发布公告称，子公司药明合联通过花旗向东曜药业发出自愿有条件现金要约，拟收购其 全部已发行股份（特定除外）并注销全部尚未行使购股权，东曜药业股份自2025年12月29日起暂停买 卖，拟于次日恢复。 此次要约每股4港元，较未受干扰日收盘价溢价约99%，较过去30个交易日平均收盘价溢价约114.67%， 较2024年12月31日每股净资产溢价约280.79%。假设要约获全面接纳，最高总代价约31.047亿港元，要 约人拟以内部资源支付。 交易关键条件是获得有效接纳股份使要约人持有不少于60%投票权，主要股东已签署不可撤销承诺。药 明合联为药明生物控股子公司，此次收购可助其拓展产能、丰富项目与客户群，巩固在ADC CDMO领 域地位。 (编辑：杨燕 林辰) ...

Policy Developments - Hunan Province has issued an implementation plan to promote provincial-level coordination of basic medical insurance, aiming to enhance the level of medical security and the fund's risk resistance by 2029 [2] Drug and Device Approvals - Zai Lab has received approval for clinical trials of injectable ZGGS18 and ZG005 for use in advanced solid tumors, although this will not significantly impact the company's recent performance [4] - Jianfeng Group has voluntarily withdrawn its clinical trial application for "C2235 and C2235 tablets," with plans to resubmit after further research [5] Capital Markets - WuXi AppTec has made a conditional cash acquisition offer of HKD 4.00 per share for all shares of Dongyao Pharmaceutical, representing a premium of approximately 114.67% over the average closing price for the last 30 trading days [7] - Yinuo Micro Pharmaceuticals has submitted a listing application to the Hong Kong Stock Exchange, with Citigroup and CICC as joint sponsors [8] Industry Events - Over 11,000 designated medical institutions are equipped to purchase 105 new drugs added to the medical insurance catalog for 2025, with 6,537 being medical institutions and 4,592 retail pharmacies [10][11] - France has launched a roadmap to address national obesity issues, setting four key objectives to curb obesity growth and improve health outcomes [12] Public Opinion Alerts - Sunflower has been investigated by the China Securities Regulatory Commission for misleading statements in its restructuring plan, leading to a 20% drop in its stock price [14]

Policy Developments - Hunan Province has issued an implementation plan to promote provincial-level coordination of basic medical insurance, aiming to enhance the level of medical security and fund risk resistance by 2029 [1] Drug and Device Approvals - Zai Lab has received clinical trial approval for injectable ZGGS18 and ZG005 for use in advanced solid tumors, although this will not significantly impact the company's recent performance [2] - Jianfeng Group has voluntarily withdrawn its clinical trial application for "C2235 and C2235 tablets," with plans to resubmit after further research [3] Capital Markets - WuXi AppTec has made a conditional cash acquisition offer of HKD 4.00 per share for all shares of Dongyao Pharmaceutical, representing a premium of approximately 114.67% over the average closing price for the previous 30 trading days [4] - Yinuo Micro Pharmaceuticals has submitted a listing application to the Hong Kong Stock Exchange, with Citigroup and CICC as joint sponsors [5] Industry Developments - Over 11,000 designated medical institutions are equipped to purchase 105 new drugs added to the 2025 medical insurance catalog, with 6,537 being medical institutions and 4,592 retail pharmacies [6][7] - France has launched a roadmap for addressing national obesity issues, with goals to curb obesity growth, improve health conditions, enhance accessibility to personalized medical services, and support innovative care methods from 2026 to 2030 [8] Public Opinion Alerts - Sunflower has been investigated by the China Securities Regulatory Commission for alleged misleading statements in its restructuring plan, leading to a 20% drop in its stock price [9]

Macro Commentary - The Chinese economy shows signs of moderate monetary policy easing, with a continued slowdown in the growth of social financing stock expected by the end of 2025, and a significant decline in M1 growth, indicating weakened economic activity and private sector confidence [2][6] - The credit structure reveals an imbalance in economic supply and demand, with the corporate sector remaining the main driver of credit expansion, while the household sector continues to deleverage [2] Global Market Performance - Major global stock indices showed varied performance, with the Hang Seng Index closing at 26,924, down 0.28% for the day but up 5.05% year-to-date [3] - The US stock market experienced a rebound, with utilities, industrials, and real estate leading gains, while energy, healthcare, and communication services sectors declined [5] Sector Performance in Hong Kong - In Hong Kong, the consumer discretionary, healthcare, and information technology sectors led declines, while real estate, energy, and industrial sectors saw gains [5] - The Hang Seng Financial Index rose by 0.68% to 50,996, while the Hang Seng Real Estate Index increased by 1.32% to 19,105 [4] Company Analysis - Jitu (1519 HK) is rated as a "Buy" with a target price of HKD 13.4, following a share swap agreement with SF Express, which is expected to enhance product offerings and market reach [6] - WuXi AppTec (2268 HK) is also rated as a "Buy" with a target price of HKD 88.00, anticipating a revenue increase of at least 45% and net profit growth of at least 38% for 2025 [7][10] - WuXi AppTec's strong performance is attributed to a record number of new contracts in drug development and production, with significant growth in XDC projects and a strategic acquisition of Dongyao Pharmaceutical to enhance production capacity [8][9][10]

野村发表报告，药明合联发盈喜，预计2025财年收入、毛利、经调整净利润及股东应占净利润按年增长 分别超过45%、70%、45%及38%。该行予其"买入"评级，目标价为82.72港元。该行推算公司2025年下 半年销售收入按年增长33%至31.8亿元，低于市场预期33.3亿元及该行原先预估34.8亿元，毛利达11.3亿 元、意味毛利率按年提升6.2个百分点至35.7%，管理层归因于产品结构优化及成本控制加强，股东应占 净利润及经调整净利润分别按年增长26%(受汇兑影响拖累)及25%，达到7.3亿元(明显低于该行及市场预 期)及8.01亿元。 ...

消息面上，药明合联和东曜药业两家ADC领域CDMO公司宣布，药明合联发出现金收购要约，以4港元/ 股价格控股收购东曜药业。据公告，相较东曜药业上一交易日收盘价2.01港元/股溢价约99%。该要约总 估值约31亿港元，要约最高代价约为27.9亿港元。 收购完成后，药明合联计划维持东曜药业上市地位，这也表明其战略意图并非私有化套利，而是战略性 控股整合，保留东曜药业作为独立运营实体，继续服务现有客户。 东曜药业-B(01875)再涨超11%，截至发稿，涨10.74%，报4.64港元，成交额2585.58万港元。 ...